Logo

Cormedix Received the US FDA’s Approval for DefenCath to Reduce Catheter-Related Bloodstream Infections (CRBSI) In Adult Hemodialysis Patients

Share this
Cormedix

Cormedix Received the US FDA’s Approval for DefenCath to Reduce Catheter-Related Bloodstream Infections (CRBSI) In Adult Hemodialysis Patients

Shots:

  • The approval was based on the P-III (LOCK-IT-100) study evaluating the safety & efficacy of DefenCath vs heparin (control) as a Catheter Lock Solution (CLS) to reduce CRBSIs in patients (n=806) with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC)
  • The result depicted a lower incidence of CRBSI in patients in the DefenCath cohort vs the control group with a Hazard Ratio of 0.29 thereby indicating a statistically significant reduction in risk of developing a CRBSI by 71%
  • DefenCath is a CLS that helps prevent infection. It contains heparin & taurolidine, an antimicrobial agent designed to occupy the catheter lumen in between sessions of dialysis

Ref: CorMedix | Image: CorMedix

Related News:- CorMedix Reports Results of Neutrolin in P-III LOCK-IT-100 Study for Patients with Hemodialysis

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions